COVID-19 has caused an unprecedented shock to European healthcare systems, leaving no components unaffected. But impacts will be felt long after the pandemic subsides, creating new patterns of health demands that systems must prepare for. In such a complex environment, the challenge is knowing where to focus, and which strategic priorities should guide healthcare system transformation.
Based on research and consultation with leading European experts, PwC Switzerland and the European Federation of Pharmaceutical Industries and Associations (EFPIA) have identified key goals and strategic directions that should be pursued by European health systems going forward to provide the population with the quality care they deserve at all times.
Strengthening the focus on prevention and early care will help preserve individual and population wellbeing, and improve system resilience alongside the evolving demand for healthcare.
By exploring future health and technology trends, healthcare systems will be able to respond to population’s evolving needs with minimal disruptions.
Leveraging the current momentum around e-health, decision makers should promote measures to strengthen digital infrastructure and incentives around remote care delivery.
Designing and co-creating care delivery around people and their needs will improve the patient experience, and rebuild trust in healthcare systems.
The shift from treatment to prevention requires the strengthening and upgrading of tools and skills. To achieve better outcomes, European healthcare systems and stakeholders should work jointly to shape and enable the delivery of relevant innovation to patients.
Responding to COVID-19 and future pressure to healthcare systems will require different stakeholders getting together around critical strategic themes. The whole study period has proven very fertile for us in building new relationships. We aim to kick-start initiatives that build on the synergies triggered by those relationships!
EFPIA and PwC encourage anyone with ideas for implementing initiatives relevant to the strategic directions we identified to reach out to us.
Getting your R&D digitally enabled is not a matter of improving your competitive edge – it’s a question of life or death. This may sound like a hyperbole, so let’s get real. Here, I discuss some avenues to trigger your R&D digital transformation in order to stay relevant in the near future.
Big pharma and life sciences organisations must adapt to the opportunities and expectations of the digital era, or risk being overtaken by nimbler newcomers. We have five tips for successful transformation. #digitalhealthcare #digitaltransformation
Companies can expect special challenges in pharmaceuticals and life sciences. We'll show you how to master them with a well-planned strategy.
Financing and controlling: PwC can provide comprehensive advice on all healthcare matters and developments to secure the future of your hospitals.
Managing Partner, Advisory and Consulting Leader, PwC Switzerland
Tel: +41 58 792 53 09
